Treats cataplexy or excessive daytime sleepiness (EDS). ANDA 203631, held by Amneal. Sodium Oxybate.
As of Nov 16, 2026, ANDA 203631 (Sodium Oxybate), held by Amneal, was first approved by FDA on Sep 10, 2025, with 0 approved supplements and 0 published complete response letters.
Sodium oxybate oral solution is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Jazz Pharmaceuticals Inc.’s XYREM (sodium oxybate) Oral Solution. However, due to Jazz Pharmaceuticals Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Oxybate0.5GM/ML · solution;oral | Sodium Oxybate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters